European Medicines Agency Expedites Review for Pancreatic Cancer Treatment

The European Medicines Agency (EMA) has initiated an accelerated, phased review for daraxonrasib, an investigational medicine targeting metastatic pancreatic cancer. This fast-track decision underscores the high unmet medical need for effective treatments for this aggressive disease. The move follows positive results from a Phase 3 study comparing the drug to chemotherapy in previously treated patients.